AMSTERDAM, Netherlands and SANTA CLARA, Calif., April 22 /PRNewswire/ -- Agendia BV, a world leader in the rapidly evolving field of molecular diagnostics, and Agilent Technologies, Inc. (NYSE: A), today announced terms under which they intend to collaborate to develop new in-vitro diagnostic tests. In addition, the two companies announced an agreement in which Agendia products will continue to be supplied on Agilent microarrays through December 31, 2011. Agilent has been manufacturing the components for the Agendia assay since its inception in 2003. The financial terms of the agreement were not disclosed.
"We've established and enjoyed a strong business relationship with Agilent since the incorporation of Agendia," said Dr. Bernhard Sixt, CEO and co- founder of Agendia. "These activities, including joint research and development, have allowed our two companies to forge an even closer strategic alliance focused on Agendia's core competencies, namely the discovery of biomarkers and development of new diagnostic tests for clinical use, which are regulated under the new IVDMIA guidelines of the FDA."
"We're proud that Agendia has selected Agilent to move forward with their critical work in diagnosing breast cancer," said Yvonne Linney, Ph.D., vice president and general manager, Genomics at Agilent. "We eagerly anticipate expanding our role beyond the manufacturing of Agendia products on the Agilent microarrays to helping them build validated diagnostic cancer tests, as well as developing and expanding the company's worldwide distribution channels."
Last year, Agendia's MammaPrint(R), a molecular diagnostic tool developed to help physicians make informed decisions in treating breast cancer, became the first IVDMIA microarray-based diagnostic test cleared by the United States Food and Drug Administration (FDA). The tests, which are manufactured on Agilent microarrays, are performed at Agendia's laboratory in The Netherlands. Agendia also offers DiscoverPrint, a gene expression-based service for improving the efficacy of clinical trials, and CupPrint, a diagnostic test designed to identify the origin of a metastasis in a cancer type called "Cancer of Unknown Primary." These are also manufactured using Agilent microarrays.
Both companies will share information about their research into genetic biomarkers and jointly assess the commercial potential of each opportunity.
About Agilent Technologies
Agilent is a leading provider of research microarrays used to analyze gene expression, microRNA, comparative genomic hybridization and ChIP-on-chip. More information about Agilent microarrays is available at http://www.opengenomics.com. Agilent Technologies Inc. (NYSE: A) is the world's premier measurement company and a technology leader in communications, electronics, life sciences and chemical analysis. The company's 19,000 employees serve customers in more than 110 countries. Agilent had net revenue of $5.4 billion in fiscal year 2007. Information about Agilent is available on the Web at http://www.agilent.com.
Agendia BV, located in Amsterdam, The Netherlands, is a world leader in
gene expression analysis-based diagnostics. With three products on the
market and an expanding market base, the company focuses on the development
and commercialization of diagnostic tests using tumor gene expression
profiling. Agendia was the first company to receive FDA clearance for its
breast cancer test, MammaPrint(R), which predicts the risk of breast cancer
recurrence. Its second microarray product, CupPrint(R)*, is a diagnostic
test designed to identify the origin of the primary tumor in "Cancer of
Unknown Primary." Agendia also recently presented data to be developed into
its new clinical colon cancer prognosis test, ColoPrint(R), which is
currently undergoing further validation. Agendia maintains close ties with
leading academic centers around the world to develop state of the art
diagnostic tests for cancer. The company also offers its expertise and its
DiscoverPrint(R) service to pharmaceutical and biotech companies focusing
on development of highly effective precision therapeutics in oncology. For
more information on Agendia, visit http://www.agendia.com.
* CupPrint(R) is based on a license to the TUO database of AviaraDx
For Agendia - EU & non-U.S.-based Media: For Agilent:
Bernhard Sixt Stuart Matlow
+31 20 512 9161 email@example.com
For Agendia - U.S. Media:
Ogilvy Public Relations Worldwide
|SOURCE Agendia BV|
Copyright©2008 PR Newswire.
All rights reserved